100 related articles for article (PubMed ID: 17878220)
21. The expression of 11β-hydroxysteroid dehydrogenase type 1 is increased in experimental periodontitis in rats.
Nakata T; Umeda M; Masuzaki H; Sawai H
BMC Oral Health; 2016 Oct; 16(1):108. PubMed ID: 27716163
[TBL] [Abstract][Full Text] [Related]
22. Idiopathic intracranial hypertension, hormones, and 11β-hydroxysteroid dehydrogenases.
Markey KA; Uldall M; Botfield H; Cato LD; Miah MA; Hassan-Smith G; Jensen RH; Gonzalez AM; Sinclair AJ
J Pain Res; 2016; 9():223-32. PubMed ID: 27186074
[TBL] [Abstract][Full Text] [Related]
23. 11β-hydroxysteroid dehydrogenase inhibition as a new potential therapeutic target for alcohol abuse.
Sanna PP; Kawamura T; Chen J; Koob GF; Roberts AJ; Vendruscolo LF; Repunte-Canonigo V
Transl Psychiatry; 2016 Mar; 6(3):e760. PubMed ID: 26978742
[TBL] [Abstract][Full Text] [Related]
24. The increased ratio of 11β-hydroxysteroid dehydrogenase type 1 versus 11β-hydroxysteroid dehydrogenase type 2 in chronic periodontitis irrespective of obesity.
Nakata T; Fujita A; Umeda M; Yoshida H; Inami K; Masuzaki H; Sawai H
Springerplus; 2016; 5():40. PubMed ID: 26835222
[TBL] [Abstract][Full Text] [Related]
25. Deletion of G-protein-coupled receptor 55 promotes obesity by reducing physical activity.
Meadows A; Lee JH; Wu CS; Wei Q; Pradhan G; Yafi M; Lu HC; Sun Y
Int J Obes (Lond); 2016 Mar; 40(3):417-24. PubMed ID: 26447738
[TBL] [Abstract][Full Text] [Related]
26. FABP4-Cre Mediated Expression of Constitutively Active ChREBP Protects Against Obesity, Fatty Liver, and Insulin Resistance.
Nuotio-Antar AM; Poungvarin N; Li M; Schupp M; Mohammad M; Gerard S; Zou F; Chan L
Endocrinology; 2015 Nov; 156(11):4020-32. PubMed ID: 26248218
[TBL] [Abstract][Full Text] [Related]
27. The gap junction blocker carbenoxolone enhances propofol and sevoflurane-induced loss of consciousness.
Liu Z; Liu Y; Zhao B; Du L; Xia Z; Chen X; Luo T
Neural Regen Res; 2012 Mar; 7(7):492-5. PubMed ID: 25745433
[TBL] [Abstract][Full Text] [Related]
28. Leukocytosis and enhanced susceptibility to endotoxemia but not atherosclerosis in adrenalectomized APOE knockout mice.
Hoekstra M; Frodermann V; van den Aardweg T; van der Sluis RJ; Kuiper J
PLoS One; 2013; 8(11):e80441. PubMed ID: 24265824
[TBL] [Abstract][Full Text] [Related]
29. 11β-HSD1 inhibitors for the treatment of type 2 diabetes and cardiovascular disease.
Anderson A; Walker BR
Drugs; 2013 Sep; 73(13):1385-93. PubMed ID: 23990334
[TBL] [Abstract][Full Text] [Related]
30. 11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.
Chapman K; Holmes M; Seckl J
Physiol Rev; 2013 Jul; 93(3):1139-206. PubMed ID: 23899562
[TBL] [Abstract][Full Text] [Related]
31. Modulation of 11β-hydroxysteroid dehydrogenase as a strategy to reduce vascular inflammation.
Hadoke PW; Kipari T; Seckl JR; Chapman KE
Curr Atheroscler Rep; 2013 May; 15(5):320. PubMed ID: 23512604
[TBL] [Abstract][Full Text] [Related]
32. 11β-hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE⁻/⁻ mice.
García RA; Search DJ; Lupisella JA; Ostrowski J; Guan B; Chen J; Yang WP; Truong A; He A; Zhang R; Yan M; Hellings SE; Gargalovic PS; Ryan CS; Watson LM; Langish RA; Shipkova PA; Carson NL; Taylor JR; Yang R; Psaltis GC; Harrity TW; Robl JA; Gordon DA
PLoS One; 2013; 8(2):e53192. PubMed ID: 23383297
[TBL] [Abstract][Full Text] [Related]
33. Carbenoxolone treatment ameliorated metabolic syndrome in WNIN/Ob obese rats, but induced severe fat loss and glucose intolerance in lean rats.
Prasad Sakamuri SS; Sukapaka M; Prathipati VK; Nemani H; Putcha UK; Pothana S; Koppala SR; Ponday LR; Acharya V; Veetill GN; Ayyalasomayajula V
PLoS One; 2012; 7(12):e50216. PubMed ID: 23284633
[TBL] [Abstract][Full Text] [Related]
34. Anatomic, hematologic, and biochemical features of C57BL/6NCrl mice maintained on chronic oral corticosterone.
Cassano AE; White JR; Penraat KA; Wilson CD; Rasmussen S; Karatsoreos IN
Comp Med; 2012 Oct; 62(5):348-60. PubMed ID: 23114038
[TBL] [Abstract][Full Text] [Related]
35. Regulation of triglyceride metabolism by glucocorticoid receptor.
Wang JC; Gray NE; Kuo T; Harris CA
Cell Biosci; 2012 May; 2(1):19. PubMed ID: 22640645
[TBL] [Abstract][Full Text] [Related]
36. G6PT-H6PDH-11βHSD1 triad in the liver and its implication in the pathomechanism of the metabolic syndrome.
Czegle I; Csala M; Mandl J; Benedetti A; Karádi I; Bánhegyi G
World J Hepatol; 2012 Apr; 4(4):129-38. PubMed ID: 22567185
[TBL] [Abstract][Full Text] [Related]
37. Antisense reduction of 11β-hydroxysteroid dehydrogenase type 1 enhances energy expenditure and insulin sensitivity independent of food intake in C57BL/6J mice on a Western-type diet.
Li G; Hernandez-Ono A; Crooke RM; Graham MJ; Ginsberg HN
Metabolism; 2012 Jun; 61(6):823-35. PubMed ID: 22209663
[TBL] [Abstract][Full Text] [Related]
38. Ablation of ghrelin receptor reduces adiposity and improves insulin sensitivity during aging by regulating fat metabolism in white and brown adipose tissues.
Lin L; Saha PK; Ma X; Henshaw IO; Shao L; Chang BH; Buras ED; Tong Q; Chan L; McGuinness OP; Sun Y
Aging Cell; 2011 Dec; 10(6):996-1010. PubMed ID: 21895961
[TBL] [Abstract][Full Text] [Related]
39. Vitamin A decreases pre-receptor amplification of glucocorticoids in obesity: study on the effect of vitamin A on 11beta-hydroxysteroid dehydrogenase type 1 activity in liver and visceral fat of WNIN/Ob obese rats.
Sakamuri VP; Ananthathmakula P; Veettil GN; Ayyalasomayajula V
Nutr J; 2011 Jun; 10():70. PubMed ID: 21696642
[TBL] [Abstract][Full Text] [Related]
40. Ablations of ghrelin and ghrelin receptor exhibit differential metabolic phenotypes and thermogenic capacity during aging.
Ma X; Lin L; Qin G; Lu X; Fiorotto M; Dixit VD; Sun Y
PLoS One; 2011 Jan; 6(1):e16391. PubMed ID: 21298106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
